Use of a Magnetic Tracer for Sentinel Lymph Node Detection in Early-Stage Breast Cancer Patients: A Meta-analysis
- 896 Downloads
Sentinel lymph node (SLN) dissection involves lymphatic mapping and selective removal of clinically negative lymph nodes at highest risk for harboring metastases. Lymphatic mapping is most often performed using radioisotope with or without blue dye (standard tracers). Sienna+®, a superparamagnetic iron oxide that can be detected using the Sentimag® magnetometer, is an alternative mapping agent to identify SLNs that has been investigated in five clinical trials. This meta-analysis was performed to determine if Sienna+® is non-inferior for SLN detection when compared to standard tracers.
Five clinical trials comparing Sienna+® to a standard technique were identified, and data from these studies were used to determine the agreement by Kappa statistic between Sienna+® and standard tracers in identifying SLNs and malignant SLNs. The trials included 1683 SLNs identified in 804 patients. Data from the studies were imbalanced, therefore additional agreement indices were utilized to compare techniques. The estimated difference between the techniques was analyzed and a margin of ≤5 % was used to determine non-inferiority.
Agreement between the Sienna+® and standard tracers was strong for SLN detection by patient [prevalence-adjusted bias-adjusted kappa (PABAK) 0.94, 95 % confidence interval (CI) 0.89–0.98], moderate to substantial for SLN detection by node (PABAK 0.68, 95 % CI 0.54–0.82), and strong for the detection of malignant SLNs by patient (PABAK 0.89, 95 % CI 0.84–0.95). Sienna+® demonstrated non-inferiority compared with standard tracers.
The Sienna+® mapping agent is non-inferior to the standard method for SLN detection in patients with clinically node-negative breast cancer.
KeywordsSentinel Lymph Node Lymphatic Mapping Positive Sentinel Lymph Node Sentinel Lymph Node Dissection Sentinel Lymph Node Detection
The University of Texas MD Anderson Cancer Center received an unrestricted educational grant from Endomagnetics, Inc. to support the statistical analyses for this study. Mediget Teshome, Caimiao Wei, Kelly K. Hunt, Alastair Thompson, Kelly Rodriguez, and Elizabeth A. Mittendorf have no additional conflicts of interest to report.
- 1.Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Del Bianco P, Zavagno G, Burelli P, et al. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomized clinical trial. Eur J Surg Oncol. 2008;34:508–13.CrossRefPubMedGoogle Scholar
- 8.Gill G; SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol. 2009;16:266–75.CrossRefPubMedGoogle Scholar
- 16.VST-1001 (Dilute Fluorescein) for lymphatic mapping and localization of lymph nodes in patients with breast cancer. ClinicalTrials.gov Identifier NCT02294565. https://clinicaltrials.gov/ct2/show/NCT02294565?term=vestan&rank=1. Accessed 20 Jun 2015.
- 17.SentiMag® intraoperative comparison in breast cancer (SentiMagIC). ClinicalTrials.gov Identifier NCT02294565. https://clinicaltrials.gov/ct2/show/NCT02336737?term=sentimag&rank=1 Accessed 20 June 2015.
- 25.Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881–8.CrossRefPubMedGoogle Scholar
- 29.Raut CP, Hunt KK, Akins JS, et al. Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol. Cancer. 2005;104:692–9.CrossRefPubMedGoogle Scholar